ProCE Banner Activity

EMPOWER-Lung 1: Cemiplimab Continuation Plus Chemotherapy After Progression on 1L Cemiplimab Monotherapy in Advanced NSCLC

Conference Coverage
Slideset

An exploratory analysis from the phase III EMPOWER-Lung 1 trial suggests that continued cemiplimab treatment plus 4 cycles of chemotherapy prolongs median PFS compared with historical data on switching to chemotherapy after progression on first-line immune checkpoint inhibitor monotherapy in patients with advanced NSCLC.

Released: April 10, 2025

Expiration: October 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc